2024-09-01 06:52:00
“Depending on demand, the manufacturer’s production capacity and financing, agreements could be signed for up to 12 million doses of vaccine in 2025”UNICEF announced in a press release issued jointly with the World Health Organization, Gavi, and the Africa Centers for Disease Control and Prevention (Africa Centers for Disease Control and Prevention).
English “Emergency tender aimed at ensuring immediate access to existing mpox vaccines and increasing production”specify the press release.
As part of the tender, UNICEF hopes to develop supply agreements that will enable it to acquire and distribute vaccines “This will be in place as soon as countries and partners secure funding, confirm demand and readiness levels and regulatory requirements for vaccine acceptance are in place”.
The resurgence of MPOX in Africa, affecting the Democratic Republic of the Congo (DRC) and other countries on the continent (notably Burundi, Kenya, Rwanda and Uganda), and the emergence of new variants (1b) prompted the World Health Organization to launch its August 14 The highest level of global health alert today.
The Democratic Republic of the Congo has reported more than 18,000 suspected cases of MPOX this year, including 629 deaths. ‘This is the center of the crisis’according to the press release, which specifies ‘Four out of five deaths involve children’.
The virus has two large families, called “clades.” Clade 1 is mainly found in the Congo Basin in central Africa. Clade 2 is prevalent mainly in West Africa.
The Democratic Republic of Congo has two MPOX subpopulations: clade 1a (in the west of the country) and clade 1b (in the east).
The World Health Organization recommends using the MVA-BN vaccine produced by the Nordic Pharmaceutical Laboratory in Bavaria, Denmark, or the LC16 vaccine produced by Japan’s KM Biologics, or the ACAM2000 vaccine produced in the United States, but the first two vaccines are not suitable for use.
MVA-BN and LC16 are not yet available “Pre-qualification” The WHO’s comprehensive review process is long and complex, and the organization has launched an emergency review.
“WHO is currently reviewing the information submitted by the manufacturer on August 23 and is expected to complete the emergency use list review in mid-September.”indicating a press release.
1725253454
#Mpox #UNICEF #launched #tender #obtain #vaccines
